Pinto Emilia Modolo, Kiseljak-Vassiliades Katja, Hantel Constanze
Pathology Department at St. Jude Children's Research Hospital, Memphis, TN, USA.
Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, Colorado, USA.
Curr Opin Endocr Metab Res. 2019 Oct;8:139-144. doi: 10.1016/j.coemr.2019.08.009. Epub 2019 Aug 29.
Adrenocortical carcinoma (ACC) is an uncommon and heterogeneous disease and may present differently in children and adults. Management of ACC is dependent on disease stage and complete surgical resection is the only potentially curative treatment. The first and most extensively used adrenocortical cancer cell line, as model system to examine mechanisms controlling normal and pathologic function of adrenal cortex, was initially isolated in 1980. Although NCI-H295 maintained steroid capabilities and adrenocortical characteristics, the lack of new cell lines and animal models of ACC has hampered the progress and development of new therapies. In this review we provide description of cellular and patient-derived tumor xenograft (PDTX) models of ACC generated for the elucidation of the underlying pathogenic mechanisms and preclinical functional studies for this aggressive disease.
肾上腺皮质癌(ACC)是一种罕见的异质性疾病,在儿童和成人中的表现可能有所不同。ACC的治疗取决于疾病分期,完整的手术切除是唯一可能治愈的治疗方法。1980年首次分离出第一个也是使用最广泛的肾上腺皮质癌细胞系,作为研究控制肾上腺皮质正常和病理功能机制的模型系统。尽管NCI-H295保留了类固醇生成能力和肾上腺皮质特征,但ACC新细胞系和动物模型的缺乏阻碍了新疗法的进展和开发。在本综述中,我们描述了为阐明这种侵袭性疾病的潜在致病机制而建立的ACC细胞和患者来源的肿瘤异种移植(PDTX)模型,以及针对该疾病的临床前功能研究。